Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587180 | 0.88 | HCRTR2 (0.57) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL29979939 | 0.85 | HTR2C (0.58) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL17234175 | 0.85 | HTR2C (0.58) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL2389760 | 0.84 | HTR2C (0.64) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL8606286 | 0.82 | HTR2C (0.70) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL9546447 | 0.81 | HTR2C (0.57) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL12282046 | 0.81 | HTR2C (0.51) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL12282385 | 0.81 | HTR2C (0.51) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL30591131 | 0.80 | HTR2C (0.47) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL15719445 | 0.80 | HTR2C (0.47) | HTR2CSMN1; SMN2NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4010314-B1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4255429-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2022119888-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | HTR2C 25/4885CACNA1G 805/4885CACNA1H 851/4885 |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | HTR2C 34/4885CACNA1G 1659/4885CACNA1H 1463/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | HTR2C 41/4885CACNA1G 1873/4885CACNA1H 1528/4885 |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | HTR2C 41/4885CACNA1G 1873/4885CACNA1H 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.